ZA84637B - Use of nafazatrom for the therapy of ischaemias,disorders in cardiac rhythm;inflammations of eye and skin;rheumatic,allergic and asthmatic diseases,ards;pulmonary embolisms;oedemes;pulmonary hypertension;oxygen intoxication;and ulcerations - Google Patents

Use of nafazatrom for the therapy of ischaemias,disorders in cardiac rhythm;inflammations of eye and skin;rheumatic,allergic and asthmatic diseases,ards;pulmonary embolisms;oedemes;pulmonary hypertension;oxygen intoxication;and ulcerations

Info

Publication number
ZA84637B
ZA84637B ZA84637A ZA84637A ZA84637B ZA 84637 B ZA84637 B ZA 84637B ZA 84637 A ZA84637 A ZA 84637A ZA 84637 A ZA84637 A ZA 84637A ZA 84637 B ZA84637 B ZA 84637B
Authority
ZA
South Africa
Prior art keywords
pulmonary
oedemes
nafazatrom
ischaemias
ulcerations
Prior art date
Application number
ZA84637A
Other languages
English (en)
Inventor
Mardin Mithat
Friedel Seuter
Wolf-Dieter Busse
Elisabeth Perzborn
Friedrich Hoffmeister
Volker Fiedler
Klaus Schlossmann
Dieter Mayer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA84637B publication Critical patent/ZA84637B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA84637A 1983-01-28 1984-01-27 Use of nafazatrom for the therapy of ischaemias,disorders in cardiac rhythm;inflammations of eye and skin;rheumatic,allergic and asthmatic diseases,ards;pulmonary embolisms;oedemes;pulmonary hypertension;oxygen intoxication;and ulcerations ZA84637B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833302811 DE3302811A1 (de) 1983-01-28 1983-01-28 Verwendung von nafazatrom bei der therapie von herzrhythmusstoerungen und myokardischaemien, arzneimittel hierfuer und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
ZA84637B true ZA84637B (en) 1984-09-26

Family

ID=6189416

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA84637A ZA84637B (en) 1983-01-28 1984-01-27 Use of nafazatrom for the therapy of ischaemias,disorders in cardiac rhythm;inflammations of eye and skin;rheumatic,allergic and asthmatic diseases,ards;pulmonary embolisms;oedemes;pulmonary hypertension;oxygen intoxication;and ulcerations

Country Status (5)

Country Link
JP (1) JPS59141517A (ja)
KR (1) KR840007356A (ja)
DE (1) DE3302811A1 (ja)
IE (1) IE840198L (ja)
ZA (1) ZA84637B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment
WO2005012255A1 (ja) * 2003-08-01 2005-02-10 Mitsubishi Pharma Corporation 炎症性関節疾患の治療剤

Also Published As

Publication number Publication date
KR840007356A (ko) 1984-12-07
IE840198L (en) 1984-07-28
DE3302811A1 (de) 1984-08-02
JPS59141517A (ja) 1984-08-14

Similar Documents

Publication Publication Date Title
Chesebro et al. Atrial fibrillation—risk marker for stroke
EP0253094A3 (en) Use of prostaglandin d2-active substances in the treatment of ocular hypertension and glaucoma
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
JPS6470040A (en) Artificial hip joint
NZ219974A (en) N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
WO1997048724A3 (en) Human metabotropic glutamate receptor
IE791235L (en) Acyl-derivatives of carnitine.
EP0350036A3 (en) Topical hematoporphyrin
EP0249736A3 (en) Ointment for the treatment of skin diseases
CA2154080A1 (en) Novel anticoagulant cofactor activity
DE3062981D1 (en) Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
ZA84637B (en) Use of nafazatrom for the therapy of ischaemias,disorders in cardiac rhythm;inflammations of eye and skin;rheumatic,allergic and asthmatic diseases,ards;pulmonary embolisms;oedemes;pulmonary hypertension;oxygen intoxication;and ulcerations
PT78239B (en) Process for preparing medicaments based on pyrazolone derivatives and process for using them as lipoxygenase inhibitors in the therapy of ischaemias and disorders in cardiac rhytm inflammations of the skin and eye and of rheumatic allergic and asthmatic diseases oedemas pulmonary embolisms pulmonary hypertension shock lung oxygen intoxication and ulcerations
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
ZA841766B (en) Use of pyrazolone derivatives as lipoxygenase inhibitors in the therapy of ischaemias and disorders in cardiac rhythm,inflammations of the skin and eye,and of rheumatic,allergic and asthmatic diseases,oedemas,pulmonary embolisms,pulmonary hypertension,shock lung,oxygen intoxication and ulcerations,medicaments for this therapy and processes for their preparation
AU4057189A (en) Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles
IT1170238B (it) Impiego di ibuprofene e flurbiprofene nella cura dell'erpete
WOLINTZ et al. Stokes-Adams syndrome and atrial arrhythmias as the presenting symptoms of myotonic dystrophy, with response to electrocardioversion
AU516531B2 (en) Method and composition forthe therapy of cerebral circulatory diseases
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
Gole et al. Familial exudative vitreoretinopathy.
NZ328915A (en) use of sulbutiamine to treat psychomotor and psychointellectual disorders
Matheson et al. The interdisciplinary team in cardiac rehabilitation.
RU2124365C1 (ru) Способ лечения ишемического инсульта